|
FDA to Pay Closer Attention to Extended-Release Generics After Teva’s Generic Wellbutrin Withdrawal
The FDA is improving its methods and standards for evaluating some extended-release generics after the withdrawal of Impax and Teva’s 300-mg Wellbutrin XL generic because the product was not therapeutically equivalent to its branded counterpart.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives